ImmunityBio (IBRX) total assets

Total assets · fiscal 2025
$501.90M

ImmunityBio (IBRX) had total assets of $501.90M at the end of fiscal 2025 (December 31, 2025). That is 31.1% higher than the $382.93M of fiscal 2024. Figures as of 18 Nov 2026, 05:05 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total assets, fiscal 2025
$501.90M
Change on fiscal 2024
+31.1%
Growth, 5 years
+17.8% a year
Growth, 10 years
+3.2% a year
Highest on record
$504.45Mfiscal 2023
Lowest on record
$143.12Mfiscal 2019
Fiscal years on record
112015–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

ImmunityBio total assets, in more detail

Over the five fiscal years to 2025 total assets grew at a compound 17.8% a year; over ten years the rate was 3.2% a year. Across the 11 fiscal years on record (2015–2025), the highest was $504.45M in fiscal 2023 and the lowest $143.12M in fiscal 2019.

History · 11 fiscal years

Total assets by fiscal year

ImmunityBio total assets, year by year

ImmunityBio (IBRX) total assets by fiscal year
Fiscal yearTotal assetsChangeYear ended
2025$501.90M 31.1% up
2024$382.93M 24.1% down
2023$504.45M 39.2% up
2022$362.36M 22.7% down
2021$468.91M 111.8% up
2020$221.38M 54.7% up
2019$143.12M 21.3% down
2018$181.95M 27.3% down
2017$250.44M 21.1% down
2016$317.50M 13.5% down
2015$366.85M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total assets is everything on the balance sheet at the fiscal year-end — cash, receivables, inventory, property, goodwill and the rest.

How to read it

It measures the resources the business has put to work; assets that grow faster than profit mean each new unit of investment is earning less.

Total assets at health care companies of similar size

Total assets of ImmunityBio and comparable companies
CompanyTotal assetsFiscal year
Alkermes ALKS$2.49B2025
PACS Group PACS$5.58B2025
Kiniksa Pharmaceuticals International KNSA$763.63M2025
ImmunityBio IBRX$501.90M2025
Cytokinetics CYTK$1.42B2025
ABIVAX ABVX€584.34M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on IBRX

ImmunityBio, figure by figure

ImmunityBio (IBRX) overview: price, valuation and scorecardAll health care companies by market value

ImmunityBio total assets: questions and answers

How large are ImmunityBio's total assets?

ImmunityBio (IBRX) had total assets of $501.90M at the end of fiscal 2025 (December 31, 2025). That is 31.1% higher than the $382.93M of fiscal 2024.

What is the growth rate of ImmunityBio's total assets?

Over the five fiscal years to 2025 total assets grew at a compound 17.8% a year; over ten years the rate was 3.2% a year.

What are the highest and lowest total assets figures on record for ImmunityBio?

Across the 11 fiscal years on record (2015–2025), the highest was $504.45M in fiscal 2023 and the lowest $143.12M in fiscal 2019.

How is ImmunityBio's total assets calculated?

Total assets is everything on the balance sheet at the fiscal year-end — cash, receivables, inventory, property, goodwill and the rest.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “ImmunityBio (IBRX) total assets”, data as of 18 November 2026. https://funkfolio.com/stock/IBRX/total-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.